Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury - Tabular View

Tracking Information

First Received Date ^ICMJE

September 12, 2005

Last Updated Date

May 15, 2009

Start Date ^ICMJE

November 1999

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00178295 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

Official Title ^ICMJE

Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

Brief Summary

Treatment for brain cancer may include radiation therapy. Radiation therapy is the treatment of tumors with X-rays. This study is related to understanding the side effects of radiation treatment for brain tumors.

This study is being conducted by the University of Rochester Cancer Center to compare the extent of side effects of brain cancer treatment with changes in levels of blood proteins called cytokines.

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Cohort, Prospective

Condition ^ICMJE

Brain Neoplasm

Intervention ^ICMJE

Radiation: Radiation Therapy

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Any patient who will be treated to the brain or spinal axis for a CNS tum Patients so treated will be stratified according to whether or not the hypo is included in the treatment fields.
Patients receiving external beam radiation to the brain may also be rece chemotherapy or interferon-beta. (Add. #1, 11-9-95)
Patients receiving high dose rate (stereotactic radiosurgery) are eligible.
Patients must sign a study specific informed consent meeting all federal a guidelines.
Patients of any age, including children, are eligible (Add. #3, 11/25/97).

Exclusion Criteria:

Patients who have a malignancy involving the hypothalamic-pituitary ax
Patients who are not treated with irradiation to the brain or spinal axis.

Gender

Both

Ages

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Louis S Constine, MD

585-275-5622

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00178295

Responsible Party

Louis Constine, Md, University of Rochester, Medical Center

Study ID Numbers ^ICMJE

URCC 11095

Study Sponsor ^ICMJE

University of Rochester

Collaborators ^ICMJE

Investigators ^ICMJE

Study Chair:	Louis S Constine, MD	Universtiy of Rochester, Dept of Radiation Oncology
Study Chair:	Ralph Brasacchio, MD	University of Rochester, Department of Radiation Oncology
Study Chair:	Paul Okunieff, MD	University of Rochester, Department of Radiation Oncology

Information Provided By

University of Rochester

Verification Date

May 2009

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP